f Toxicity Concerns Associated with the Radiopharmaceuticals for the Diagnosis of Alzheimer’s Disease

References

1. FilippiL. ChiaravallotiA. BagniO. SchillaciO. 18F-labeled radiopharmaceuticals for the molecular neuroimaging of amyloid plaques in Alzheimer’s disease.Am. J. Nucl. Med. Mol. Imaging201884268281 30245918
   [Google Scholar]
2. GrillJ.D. JohnsonD.K. BurnsJ.M. Should we disclose amyloid imaging results to cognitively normal individuals?Neurodegener. Dis. Manag.201331435110.2217/nmt.12.75 25285157
   [Google Scholar]
3. CarneiroC.G. FariaD.P. CoutinhoA.M. OnoC.R. DuranF.L.S. da CostaN.A. GarcezA.T. da SilveiraP.S. ForlenzaO.V. BruckiS.M.D. NitriniR. Busatto FilhoG. BuchpigueC.A. Evaluation of 10-minute post-injection 11C-PiB PET and its correlation with 18F-FDG PET in older adults who are cognitively healthy, mildly impaired, or with probable Alzheimer’s disease.Rev. Bras. Psiquiatr.202244549550610.47626/1516‑4446‑2021‑2374 36420910
   [Google Scholar]
4. AuvityS. ToniettoM. CailléF. BodiniB. BottlaenderM. TournierN. KuhnastB. StankoffB. Repurposing radiotracers for myelin imaging: A study comparing 18F-florbetaben, 18F-florbetapir, 18F-flutemetamol,11C-MeDAS, and 11C-PiB.Eur. J. Nucl. Med. Mol. Imaging202047249050110.1007/s00259‑019‑04516‑z 31686177
   [Google Scholar]
5. RaiH. GuptaS. KumarS. YangJ. SinghS.K. RanC. ModiG. Near-infrared fluorescent probes as imaging and theranostic modalities for amyloid-beta and tau aggregates in Alzheimer’s disease.J. Med. Chem.202265138550859510.1021/acs.jmedchem.1c01619 35759679
   [Google Scholar]
6. GrimmerT. ShiK. Diehl-SchmidJ. NataleB. DrzezgaA. FörsterS. FörstlH. SchwaigerM. YakushevI. WesterH.J. KurzA. YousefiB.H. 18F-FIBT may expand PET for β-amyloid imaging in neurodegenerative diseases.Mol. Psychiatry202025102608261910.1038/s41380‑018‑0203‑5 30120417
   [Google Scholar]
7. CrișanG. Moldovean-CioroianuN.S. TimaruD.G. AndrieșG. CăinapC. ChișV. Radiopharmaceuticals for PET and SPECT imaging: A literature review over the last decade.Int. J. Mol. Sci.2022239502310.3390/ijms23095023 35563414
   [Google Scholar]
8. VillemagneV.L. FurumotoS. Fodero-TavolettiM. HaradaR. MulliganR.S. KudoY. MastersC.L. YanaiK. RoweC.C. OkamuraN. The challenges of tau imaging.Future Neurol.20127440942110.2217/fnl.12.34
   [Google Scholar]
9. MuellerA. BullichS. BarretO. MadoniaJ. BerndtM. PapinC. PerrotinA. KoglinN. KrothH. PfeiferA. TamagnanG. SeibylJ.P. MarekK. De SantiS. DinkelborgL.M. StephensA.W. Tau PET imaging with 18F-PI-2620 in patients with Alzheimer disease and healthy controls: A first-in-humans study.J. Nucl. Med.202061691191910.2967/jnumed.119.236224 31712323
   [Google Scholar]
10. UzuegbunamB.C. LibrizziD. Hooshyar YousefiB. PET radiopharmaceuticals for Alzheimer’s disease and Parkinson’s disease diagnosis, the current and future landscape.Molecules202025497710.3390/molecules25040977 32098280
    [Google Scholar]
11. YeoJ.M. WaddellB. KhanZ. PalS. A systematic review and meta‐analysis of 18 F‐labeled amyloid imaging in Alzheimer’s disease.Alzheimers Dement.20151151310.1016/j.dadm.2014.11.004 27239488
    [Google Scholar]
12. ThientunyakitT. SethanandhaC. MuangpaisanW. ChawalparitO. ArunrungvichianK. SiriprapaT. ThongpraparnT. ChanachaiR. GelovaniJ. Implementation of [18F]-labeled amyloid brain PET imaging biomarker in the diagnosis of Alzheimer’s disease.Nucl. Med. Commun.201839218619210.1097/MNM.0000000000000787 29334579
    [Google Scholar]
13. CistaroA. AlongiP. CaobelliF. CassaliaL. Radiotracers for amyloid imaging in neurodegenerative disease: State-of-the-art and novel concepts.Curr. Med. Chem.201825263131314010.2174/0929867325666180117094704 29345576
    [Google Scholar]
14. TiepoltS. HesseS. PattM. LuthardtJ. SchroeterM.L. HoffmannK.T. WeiseD. GertzH.J. SabriO. BarthelH. Early [18F]florbetaben and [11C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer’s disease.Eur. J. Nucl. Med. Mol. Imaging20164391700170910.1007/s00259‑016‑3353‑1 27026271
    [Google Scholar]
15. VillemagneV.L. MulliganR.S. PejoskaS. OngK. JonesG. O’KeefeG. ChanJ.G. YoungK. Tochon-DanguyH. MastersC.L. RoweC.C. Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer’s disease.Eur. J. Nucl. Med. Mol. Imaging201239698398910.1007/s00259‑012‑2088‑x 22398958
    [Google Scholar]
16. ZhangH. WeiW. ZhaoM. MaL. JiangX. PeiH. CaoY. LiH. Interaction between Aβ and tau in the pathogenesis of Alzheimer’s disease.Int. J. Biol. Sci.20211792181219210.7150/ijbs.57078 34239348
    [Google Scholar]
17. BulicB. PickhardtM. SchmidtB. MandelkowE.M. WaldmannH. MandelkowE. Development of tau aggregation inhibitors for Alzheimer’s disease.Angew. Chem. Int. Ed.200948101740175210.1002/anie.200802621 19189357
    [Google Scholar]
18. GuoJ.P. AraiT. MiklossyJ. McGeerP.L. Aβ and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer’s disease.Proc. Natl. Acad. Sci. USA200610361953195810.1073/pnas.0509386103 16446437
    [Google Scholar]